Skip to content

Study · Animal study (in vivo) · mouse · 2004

5 results

Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells.

Shrivastava P, Singh SM, Singh N

Journal of biomedical science1 Sept 2004Cited by 20 (Europe PMC)

PMID15316138 (opens in a new tab)DOI10.1007/bf02256128 (opens in a new tab)PepBankPUB-15316138
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    Dendritic cells generated from tumor-bearing mice given thymosin alpha‑1 showed augmented antitumor activity in vitro.

    In plain wordsIn mice with lymphoma, dendritic cells from animals given thymosin alpha‑1 showed stronger antitumor activity in lab tests.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseAntitumor activity of TAM-derived DC in vitro
    Study

    mousen: not reported in source

    Mice bearing Dalton's lymphoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was observed that DC generated from thyalpha1-administered tumor-bearing mice showed augmented antitumor activity in vitro.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    Dendritic cells obtained from tumor-associated macrophages of mice given thymosin alpha‑1 produced more IL-1.

    In plain wordsIn mice with lymphoma, dendritic cells from animals given thymosin alpha‑1 made more IL-1.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-1 production by DC from TAM
    Study

    mousen: not reported in source

    Mice bearing Dalton's lymphoma
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    DC obtained from TAM of thyalpha1-administered mice also produced an enhanced amount of cytokines like IL-1 and TNF-alpha.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    Dendritic cells obtained from tumor-associated macrophages of mice given thymosin alpha‑1 produced more TNF-alpha.

    In plain wordsIn mice with lymphoma, dendritic cells from animals given thymosin alpha‑1 made more TNF-alpha.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTNF-alpha production by DC from TAM
    Study

    mousen: not reported in source

    Mice bearing Dalton's lymphoma
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    DC obtained from TAM of thyalpha1-administered mice also produced an enhanced amount of cytokines like IL-1 and TNF-alpha.

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In tumor-bearing mice, adoptive immunotherapy with TAM-derived dendritic cells significantly delayed tumor growth.

    In plain wordsIn mice with lymphoma, transfer of dendritic cells derived from tumor-associated macrophages delayed tumor growth.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumor growth after adoptive immunotherapy with TAM-derived DC
    Study

    mousen: not reported in source

    Mice bearing Dalton's lymphoma
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Adoptive immunotherapy using TAM-derived DC showed a significant delay in the tumor growth and a prolongation of the survival time in tumor-bearing mice.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In tumor-bearing mice, adoptive immunotherapy with TAM-derived dendritic cells prolonged survival time.

    In plain wordsIn mice with lymphoma, transfer of dendritic cells derived from tumor-associated macrophages extended survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival time after adoptive immunotherapy with TAM-derived DC
    Study

    mousen: not reported in source

    Mice bearing Dalton's lymphoma
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    a prolongation of the survival time in tumor-bearing mice.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.